You are here

Regeneron

Regeneron Focuses on Expanding Eylea’s Diabetic Retinopathy Label

Regeneron Focuses on Expanding Eylea’s Diabetic Retinopathy Label

Market Realist

diabetic retinopathy

Flag link:

With $460B in borrowing capacity, will any of the Big-20 biopharmas go after one of the top-5 takeover targets?

With $460B in borrowing capacity, will any of the Big-20 biopharmas go after one of the top-5 takeover targets?

Endpoints

Gilead Sciences

Flag link:

Biopharma M&A: You Ain’t Seen Nothing Yet

Biopharma M&A: You Ain’t Seen Nothing Yet

Barron's

Gilead Sciences

Flag link:

5 takeaways from the first look at cancer's biggest conference

5 takeaways from the first look at cancer's biggest conference

Biopharma Dive

Bristol-Myers Squibb

Jounce Therapeutics

Flag link:

Are These Disappointing Drugs Back on Track to Billions?

Are These Disappointing Drugs Back on Track to Billions?

Motley Fool

PCSK9 inhibitors

Flag link:

3 Reasons Regeneron Stock Could Start Climbing Again

3 Reasons Regeneron Stock Could Start Climbing Again

Yahoo/Motley Fool

Flag link:

Regeneron halts high doses of phase 3 osteoarthritis drug fasinumab amid risk-benefit concerns

Regeneron halts high doses of phase 3 osteoarthritis drug fasinumab amid risk-benefit concerns

Fierce Biotech

clinical trials

Flag link:

Regeneron (REGN) Q1 Earnings Top, Sales Lag, Updates View

Regeneron (REGN) Q1 Earnings Top, Sales Lag, Updates View

Yahoo/Zacks.com

Flag link:

Express Scripts Picks Regeneron Over Amgen, Cuts Heart Drug Price

Express Scripts Picks Regeneron Over Amgen, Cuts Heart Drug Price

Xconomy

Express Scripts

Flag link:

Eyeing Eylea’s $5B sales, Novartis touts solid 12-week dosing data for its rival RTH258

Eyeing Eylea’s $5B sales, Novartis touts solid 12-week dosing data for its rival RTH258

Endpoints

wet age-related macular degeneration

Flag link:

Regeneron/Sanofi circle October 28 on the calendar as the FDA begins a speedy review of the world’s 6th PD-1/L1 checkpoint

Regeneron/Sanofi circle October 28 on the calendar as the FDA begins a speedy review of the world’s 6th PD-1/L1 checkpoint

Endpoints

PD-1 inhibitors

Flag link:

Biotech stars Schleifer and Yancopoulos share $52M in 2017 compensation, even though Regeneron’s share price swooned

Biotech stars Schleifer and Yancopoulos share $52M in 2017 compensation, even though Regeneron’s share price swooned

Endpoints

George Yancopoulos

Flag link:

Novartis sues Regeneron over manufacturing methods

Novartis sues Regeneron over manufacturing methods

Biopharma Dive

drug manufacturing

Flag link:

Regeneron, Alnylam partner to turn discovery into new drugs for NASH

Regeneron, Alnylam partner to turn discovery into new drugs for NASH

Biopharma Dive

Flag link:

Regeneron’s Eylea Shows Promise in Late-Stage Diabetic Retinopathy Trial

Regeneron’s Eylea Shows Promise in Late-Stage Diabetic Retinopathy Trial

Xtalks

diabetic retinopathy

Flag link:

With Novartis and Roche gunning to carve up Eylea franchise, Regeneron has another PhIII success story to tell

With Novartis and Roche gunning to carve up Eylea franchise, Regeneron has another PhIII success story to tell

Endpoints

Flag link:

Amgen faces tough one-two blow as competition mounts for Repatha and Sensipar

Amgen faces tough one-two blow as competition mounts for Repatha and Sensipar

Fierce Pharma

Flag link:

Regeneron/Sanofi heart drug succeeds in major trial; Will insurers pay?

Regeneron/Sanofi heart drug succeeds in major trial; Will insurers pay?

Yahoo/Reuters

clinical trials

Flag link:

Regeneron to Slash Price of Cholesterol Drug After Showing it Saved Lives

Regeneron to Slash Price of Cholesterol Drug After Showing it Saved Lives

Xconomy

Flag link:

Here's What Weighed on Regeneron Pharmaceuticals Inc. in February

Here's What Weighed on Regeneron Pharmaceuticals Inc. in February

Motley Fool

Flag link:

Pages